Acute myeloid leukaemia (AML) is an aggressive blood cancer that looks different from one patient to the next and the disease even changes over time within the same patient. Two international research teams (AML_PM and MetaboTargetAML) have developed cutting-edge ways to “read” what AML cells are doing, based on their cellular signals, protein they express and their energy use. This networking meeting will bring together physicians, researchers, data and AI scientists, biobank specialists, and patient representatives to turn those advances into practical tools for patient care. The project aim to agree on

1. how to standardise advanced blood tests using cutting edge new technology so physicians can diagnose AML and track tiny amounts of leftover disease more reliably,
2. set up a single-cell testing pipeline that can be confirmed with advanced gene sequencing and protein analysis,
3. align AI tools to sort patients into the right treatment groups,
4. agree on shared rules for biobanking and trustworthy data sharing,
5. address ethics and regulation issues (privacy, responsible AI, cross-border data), and
6. design a joint plan to ensure follow-up funding.

The partners aim to deliver a shared test protocol for key AML biomarkers, a plan to connect data and AI, stronger patient-centred involvement, and a draft pathway to bring these methods into clinics and future trials faster. The two-day, in-person workshop will be held towards the end of 2026 and host up to 40 participants to ensure focused work and concrete outputs.